Royal Bank Of Canada Reaffirms Outperform Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report)'s stock had its "outperform" rating reaffirmed by equities research analysts at Royal Bank Of Canada in a research note issued to investors on Monday,Benzinga reports. They presently have a $13.00 price target on the biotechnology company's stock. Royal Bank Of Canada's price target suggests a potential upside of 45.33% from the company's previous close.

BCRX has been the subject of several other research reports. Needham & Company LLC reissued a "buy" rating and issued a $17.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, June 25th. Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price target for the company. JPMorgan Chase & Co. upped their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Wedbush boosted their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a report on Monday. Finally, HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $16.70.

BioCryst Pharmaceuticals Stock Down 0.8%

Shares of BCRX stock traded down $0.08 during mid-day trading on Monday, reaching $8.95. 1,407,127 shares of the stock traded hands, compared to its average volume of 3,032,538. The stock's fifty day simple moving average is $10.03 and its two-hundred day simple moving average is $8.58. BioCryst Pharmaceuticals has a 1-year low of $6.02 and a 1-year high of $11.31. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -34.40, a price-to-earnings-growth ratio of 2.58 and a beta of 1.04.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Headlands Technologies LLC bought a new position in BioCryst Pharmaceuticals in the 1st quarter valued at $32,000. GF Fund Management CO. LTD. purchased a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter worth $33,000. GAMMA Investing LLC boosted its stake in BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after buying an additional 5,449 shares during the period. New Age Alpha Advisors LLC bought a new stake in BioCryst Pharmaceuticals during the first quarter valued at $62,000. Finally, Allspring Global Investments Holdings LLC purchased a new position in BioCryst Pharmaceuticals during the first quarter worth about $79,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.